$IMUX
Immunic Inc

2020 Q1 Form 10-K Financial Statement

#000128077620000009 Filed on March 16, 2020

View on sec.gov

Income Statement

Concept 2020 Q1 2019 2018 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.580M $14.52M $2.530M
YoY Change 96.95% 6.84% -44.88%
% of Gross Profit
Research & Development $6.434M $22.51M $150.0K
YoY Change 91.77% 134.62% -98.53%
% of Gross Profit
Depreciation & Amortization $14.00K $50.00K $100.0K
YoY Change 180.0% 233.33% -54.55%
% of Gross Profit
Operating Expenses $9.014M $37.03M $5.234M
YoY Change 93.35% 208.68% -64.59%
Operating Profit -$9.014M -$37.03M
YoY Change 93.35% 208.68%
Interest Expense $20.00K $110.0K $80.00K
YoY Change -78.85% -60.0%
% of Operating Profit
Other Income/Expense, Net $527.0K $2.099M $10.00K
YoY Change 51.0% 361.32% -200.0%
Pretax Income -$8.490M -$34.93M -$2.460M
YoY Change 96.98% -15.78% -83.14%
Income Tax
% Of Pretax Income
Net Earnings -$8.487M -$34.93M -$4.812M
YoY Change 96.78% 202.66% -67.01%
Net Earnings / Revenue
Basic Earnings Per Share -$0.79
Diluted Earnings Per Share -$0.79 -$4.525M -$2.321M
COMMON SHARES
Basic Shares Outstanding 10.74M shares 42.37M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q1 2019 2018 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $18.60M $29.40M $13.30M
YoY Change 93.75% 121.05% -76.63%
Cash & Equivalents $18.60M $29.40M $13.07M
Short-Term Investments
Other Short-Term Assets $670.0K $2.900M $68.00K
YoY Change 67.5% 222.22% -94.33%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $23.60M $32.20M $13.33M
YoY Change 136.27% 126.76% -77.06%
LONG-TERM ASSETS
Property, Plant & Equipment $77.00K $700.0K $40.00K
YoY Change -84.02% 0.0% -98.14%
Goodwill $32.97M $0.00
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $42.00K $0.00 $0.00
YoY Change 250.0% -100.0%
Total Long-Term Assets $33.69M $33.80M $40.00K
YoY Change 6720.45% 4125.0% -98.23%
TOTAL ASSETS
Total Short-Term Assets $23.60M $32.20M $13.33M
Total Long-Term Assets $33.69M $33.80M $40.00K
Total Assets $57.29M $66.00M $13.37M
YoY Change 446.58% 340.0% -77.86%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.432M $2.400M $1.400M
YoY Change 678.26% 700.0% 33.46%
Accrued Expenses $3.963M $3.300M $416.0K
YoY Change 226.17% 50.0% -95.45%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $6.333M $7.100M $1.920M
YoY Change 341.94% 184.0% -81.32%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $500.0K $500.0K $0.00
YoY Change -100.0%
Total Long-Term Liabilities $471.0K $500.0K $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.333M $7.100M $1.920M
Total Long-Term Liabilities $471.0K $500.0K $0.00
Total Liabilities $6.804M $7.600M $1.920M
YoY Change 374.81% 192.31% -81.43%
SHAREHOLDERS EQUITY
Retained Earnings -$68.40M -$25.00M
YoY Change -80.28% -91.55%
Common Stock $1.000K $0.00
YoY Change -75.0% -100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $50.49M $58.40M -$25.74M
YoY Change
Total Liabilities & Shareholders Equity $57.29M $66.00M $13.37M
YoY Change 446.58% 340.0% -77.86%

Cashflow Statement

Concept 2020 Q1 2019 2018 Q4
OPERATING ACTIVITIES
Net Income -$8.487M -$34.93M -$4.812M
YoY Change 96.78% 202.66% -67.01%
Depreciation, Depletion And Amortization $14.00K $50.00K $100.0K
YoY Change 180.0% 233.33% -54.55%
Cash From Operating Activities -$11.03M -$28.55M -$4.660M
YoY Change 107.43% 193.13% -53.02%
INVESTING ACTIVITIES
Capital Expenditures $4.000K $55.00K $0.00
YoY Change -42.86% 71.88% -100.0%
Acquisitions
YoY Change
Other Investing Activities $10.59M $180.0K
YoY Change 5783.33%
Cash From Investing Activities -$4.000K $10.54M $180.0K
YoY Change -42.86% -33025.0% -263.64%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $568.0K $34.90M 0.000
YoY Change -97.23% 81.22% -100.0%
NET CHANGE
Cash From Operating Activities -$11.03M -$28.55M -4.660M
Cash From Investing Activities -$4.000K $10.54M 180.0K
Cash From Financing Activities $568.0K $34.90M 0.000
Net Change In Cash -$10.79M $16.30M -4.480M
YoY Change -172.2% 90.21% -52.79%
FREE CASH FLOW
Cash From Operating Activities -$11.03M -$28.55M -$4.660M
Capital Expenditures $4.000K $55.00K $0.00
Free Cash Flow -$11.03M -$28.60M -$4.660M
YoY Change 107.23% 192.73% -52.45%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019 dei Entity Central Index Key
EntityCentralIndexKey
0001280776
CY2019 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
CY2019 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2019 dei Amendment Flag
AmendmentFlag
false
CY2019 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2019Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.025
CY2019 dei Document Type
DocumentType
10-K
CY2019 dei Document Type
DocumentType
10-K
CY2019 dei Document Annual Report
DocumentAnnualReport
true
CY2019 dei Document Period End Date
DocumentPeriodEndDate
2019-12-31
CY2019 dei Document Transition Report
DocumentTransitionReport
false
CY2019 dei Entity File Number
EntityFileNumber
001-36201
CY2019 dei Entity Registrant Name
EntityRegistrantName
Immunic, Inc.
CY2019 dei Entity Small Business
EntitySmallBusiness
true
CY2019 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2019 dei Entity Shell Company
EntityShellCompany
false
CY2019Q2 dei Entity Public Float
EntityPublicFloat
50800000 USD
CY2020Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
10744806 shares
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
29369000 USD
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13072000 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2861000 USD
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
259000 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
32230000 USD
CY2018Q4 us-gaap Assets Current
AssetsCurrent
13331000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
80000 USD
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
40000 USD
CY2019Q4 us-gaap Goodwill
Goodwill
32970000 USD
CY2018Q4 us-gaap Goodwill
Goodwill
0 USD
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
633000 USD
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
42000 USD
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
0 USD
CY2019Q4 us-gaap Assets
Assets
65955000 USD
CY2018Q4 us-gaap Assets
Assets
13371000 USD
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2423000 USD
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1400000 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3298000 USD
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
416000 USD
CY2019Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1351000 USD
CY2018Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
104000 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7072000 USD
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1920000 USD
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
520000 USD
CY2019Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
520000 USD
CY2018Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
0 USD
CY2019Q4 us-gaap Liabilities
Liabilities
7592000 USD
CY2018Q4 us-gaap Liabilities
Liabilities
1920000 USD
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
130000000 shares
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
846953 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10744806 shares
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10744806 shares
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
846953 shares
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
846953 shares
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
1000 USD
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
0 USD
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
119646000 USD
CY2018Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
56000 USD
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1373000 USD
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-819000 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-59911000 USD
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-24978000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
58363000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-25741000 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
65955000 USD
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13371000 USD
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22512000 USD
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9595000 USD
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14520000 USD
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2402000 USD
CY2019 us-gaap Operating Expenses
OperatingExpenses
37032000 USD
CY2018 us-gaap Operating Expenses
OperatingExpenses
11997000 USD
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-37032000 USD
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-11997000 USD
CY2019 us-gaap Investment Income Interest
InvestmentIncomeInterest
107000 USD
CY2018 us-gaap Investment Income Investment Expense
InvestmentIncomeInvestmentExpense
1000 USD
CY2019 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1992000 USD
CY2018 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
456000 USD
CY2019 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2099000 USD
CY2018 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
455000 USD
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-34933000 USD
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-11542000 USD
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.52
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-13.63
CY2019 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2019 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
56-2358443
CY2019 dei Entity Address Address Line1
EntityAddressAddressLine1
1200 Avenue of the Americas,
CY2019 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 200
CY2019 dei Entity Address City Or Town
EntityAddressCityOrTown
New York,
CY2019 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2019 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10036
CY2019 dei City Area Code
CityAreaCode
858
CY2019 dei Local Phone Number
LocalPhoneNumber
673-6840
CY2019 dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value
CY2019 dei Trading Symbol
TradingSymbol
IMUX
CY2019 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2019 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2019 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2019 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2019 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2019 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
7722269 shares
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
846953 shares
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-34933000 USD
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-11542000 USD
CY2019 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-554000 USD
CY2018 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-862000 USD
CY2019 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-35487000 USD
CY2018 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12404000 USD
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
-13337000 USD
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-11542000 USD
CY2018 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-862000 USD
CY2018 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
0 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-25741000 USD
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-34933000 USD
CY2019 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-554000 USD
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
529000 USD
CY2019 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
72300000 USD
CY2019 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
37193000 USD
CY2019 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
39400000 USD
CY2019 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
0 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
58363000 USD
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-34933000 USD
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-11542000 USD
CY2019 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
50000 USD
CY2018 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
15000 USD
CY2019 us-gaap Gain Loss On Sale Of Equity Investments
GainLossOnSaleOfEquityInvestments
329000 USD
CY2018 us-gaap Gain Loss On Sale Of Equity Investments
GainLossOnSaleOfEquityInvestments
0 USD
CY2019 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
26000 USD
CY2018 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-1000 USD
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
6512000 USD
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
0 USD
CY2019 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
1540000 USD
CY2018 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0 USD
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2224000 USD
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-218000 USD
CY2019 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-462000 USD
CY2018 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1200000 USD
CY2019 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1102000 USD
CY2018 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1000 USD
CY2019 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
225000 USD
CY2018 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
369000 USD
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-28545000 USD
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9738000 USD
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
55000 USD
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
32000 USD
CY2019 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
75000 USD
CY2018 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
0 USD
CY2019 us-gaap Proceeds From Sale Of Other Property Plant And Equipment
ProceedsFromSaleOfOtherPropertyPlantAndEquipment
2475000 USD
CY2018 us-gaap Proceeds From Sale Of Other Property Plant And Equipment
ProceedsFromSaleOfOtherPropertyPlantAndEquipment
0 USD
CY2019 imux Cash Acquired In Connection With Reverse Acquisition
CashAcquiredInConnectionWithReverseAcquisition
8151000 USD
CY2018 imux Cash Acquired In Connection With Reverse Acquisition
CashAcquiredInConnectionWithReverseAcquisition
0 USD
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-25000000.0 USD
CY2019 us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
40000 USD
CY2018 us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
0 USD
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
10536000 USD
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-32000 USD
CY2019 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
CY2018 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
19256000 USD
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
29965000 USD
CY2018 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 USD
CY2019 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
5200000 USD
CY2018 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
0 USD
CY2019 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
270000 USD
CY2018 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0 USD
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
34895000 USD
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
19256000 USD
CY2019 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-589000 USD
CY2018 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-918000 USD
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
16297000 USD
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
8568000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13072000 USD
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4504000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
29369000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13072000 USD
CY2019 imux Deferred Financing Costs Included In Liabilities
DeferredFinancingCostsIncludedInLiabilities
0 USD
CY2018 imux Deferred Financing Costs Included In Liabilities
DeferredFinancingCostsIncludedInLiabilities
1000 USD
CY2019 imux Deferred Stock Issuance Costs Included In Liabilities
DeferredStockIssuanceCostsIncludedInLiabilities
20000 USD
CY2018 imux Deferred Stock Issuance Costs Included In Liabilities
DeferredStockIssuanceCostsIncludedInLiabilities
0 USD
CY2019 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
37193000 USD
CY2018 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
0 USD
CY2019 us-gaap Noncash Or Part Noncash Acquisition Value Of Assets Acquired1
NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1
39400000 USD
CY2018 us-gaap Noncash Or Part Noncash Acquisition Value Of Assets Acquired1
NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1
0 USD
CY2019 imux Property Plant And Equipment Included In Accounts Payable
PropertyPlantAndEquipmentIncludedInAccountsPayable
19000 USD
CY2018 imux Property Plant And Equipment Included In Accounts Payable
PropertyPlantAndEquipmentIncludedInAccountsPayable
0 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-59900000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
29400000 USD
CY2019 us-gaap Use Of Estimates
UseOfEstimates
<div style="text-indent:22.5pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and the disclosure of contingent assets and liabilities in the Company’s consolidated financial statements. The most significant estimates in the Company’s financial statements and accompanying notes relate to the application of the acquisition method of accounting related to the Transaction, clinical trial expenses, share-based compensation and notes related to contractual obligations. Management believes its estimates to be reasonable under the circumstances. Actual results could differ materially from those estimates and assumptions.</span></div>
CY2019 imux Cash Equivalents Investments Maturity Period
CashEquivalentsInvestmentsMaturityPeriod
P3M
CY2019 us-gaap Depreciation And Amortization
DepreciationAndAmortization
50000 USD
CY2018 us-gaap Depreciation And Amortization
DepreciationAndAmortization
15000 USD
CY2019 us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
0 USD
CY2018 us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
0 USD
CY2019 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
CY2019 imux Short Term Lease Term
ShortTermLeaseTerm
P12M
CY2019Q4 imux Lessee Operating Leases Number Of Existing Leases
LesseeOperatingLeasesNumberOfExistingLeases
4 lease
CY2019 imux Business Combination Separately Recognized Transactions Additional Disclosures Acquisition Cost Expensed Non Cash Charges
BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensedNonCashCharges
7500000 USD
CY2019Q4 imux Research And Development Tax Incentive Current
ResearchAndDevelopmentTaxIncentiveCurrent
350000 USD
CY2018Q4 imux Research And Development Tax Incentive Current
ResearchAndDevelopmentTaxIncentiveCurrent
0 USD
CY2019 us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
0 USD
CY2018 us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
0 USD
CY2019 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-19295000 USD
CY2018 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-53017000 USD
CY2019Q4 imux Prepaid Clinical And Related Costs Current
PrepaidClinicalAndRelatedCostsCurrent
1307000 USD
CY2018Q4 imux Prepaid Clinical And Related Costs Current
PrepaidClinicalAndRelatedCostsCurrent
0 USD
CY2019Q4 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
408000 USD
CY2018Q4 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
191000 USD
CY2019Q4 us-gaap Other Assets Current
OtherAssetsCurrent
796000 USD
CY2018Q4 us-gaap Other Assets Current
OtherAssetsCurrent
68000 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2861000 USD
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
259000 USD
CY2019Q4 imux Clinical Costs Payable Current
ClinicalCostsPayableCurrent
1981000 USD
CY2018Q4 imux Clinical Costs Payable Current
ClinicalCostsPayableCurrent
1065000 USD
CY2019Q4 imux Legal And Audit Costs Payable Current
LegalAndAuditCostsPayableCurrent
226000 USD
CY2018Q4 imux Legal And Audit Costs Payable Current
LegalAndAuditCostsPayableCurrent
291000 USD
CY2019Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
216000 USD
CY2018Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
44000 USD
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2423000 USD
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1400000 USD
CY2019Q4 imux Accrued Clinical Costs Current
AccruedClinicalCostsCurrent
2863000 USD
CY2018Q4 imux Accrued Clinical Costs Current
AccruedClinicalCostsCurrent
197000 USD
CY2019Q4 imux Accrued Legal And Audit Costs Current
AccruedLegalAndAuditCostsCurrent
211000 USD
CY2018Q4 imux Accrued Legal And Audit Costs Current
AccruedLegalAndAuditCostsCurrent
102000 USD
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
224000 USD
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
117000 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3298000 USD
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
416000 USD
CY2019Q4 us-gaap Other Deferred Credits Current
OtherDeferredCreditsCurrent
1008000 USD
CY2018Q4 us-gaap Other Deferred Credits Current
OtherDeferredCreditsCurrent
0 USD
CY2019Q4 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
343000 USD
CY2018Q4 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
104000 USD
CY2019Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1351000 USD
CY2018Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
104000 USD
CY2019 imux Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
600000 USD
CY2019Q4 imux Operating Lease Incremental Borrowing Rate
OperatingLeaseIncrementalBorrowingRate
0.06
CY2019 imux Operating And Variable Leases Cost
OperatingAndVariableLeasesCost
135000 USD
CY2018 imux Operating And Variable Leases Cost
OperatingAndVariableLeasesCost
45000 USD
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
193000 USD
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
270000 USD
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
224000 USD
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
75000 USD
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
0 USD
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
0 USD
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
762000 USD
CY2019Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
76000 USD
CY2019Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
686000 USD
CY2019Q4 us-gaap Contractual Obligation
ContractualObligation
2800000 USD
CY2016Q2 imux Asset Purchase Agreement Royalties As Percent Of Aggregated Net Sales
AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales
0.044
CY2019Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
120070 shares
CY2019Q2 us-gaap Common Stock Value
CommonStockValue
1500000 USD
CY2018Q2 imux Maximum Aggregate Offering Priceof Securities Under Shelf Registration
MaximumAggregateOfferingPriceofSecuritiesUnderShelfRegistration
200000000.0 USD
CY2018Q2 imux Maximum Number Of Common Shares That Can Be Sold Under Shelf Registration Statement By Selling Shareholders
MaximumNumberOfCommonSharesThatCanBeSoldUnderShelfRegistrationStatementBySellingShareholders
2500000 shares
CY2018Q2 imux Maximum Amount Of Common Stock That Can Be Issued Under At The Market Sales Agreement
MaximumAmountOfCommonStockThatCanBeIssuedUnderAtTheMarketSalesAgreement
60000000.0 USD
CY2019Q3 imux Maximum Aggregate Offering Priceof Securities Under Shelf Registration
MaximumAggregateOfferingPriceofSecuritiesUnderShelfRegistration
40000000.0 USD
CY2019 imux Shelf Registration Agreement Commission Percent Of Gross Proceeds On Sale Of Common Stock
ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock
0.030
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
846953 shares
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
1.00
CY2016Q2 us-gaap Common Stock Value
CommonStockValue
56000 USD
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
130000000 shares
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2018 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0
CY2019Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
3719.60
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2018 us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0
CY2019 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0
CY2019 us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0
CY2019Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
1603964 shares
CY2019Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
3300000 USD
CY2019 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y29D
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.000
CY2019 us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
-44759000 USD
CY2018 us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
-11542000 USD
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.275
CY2019 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.011
CY2018 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.000
CY2018 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.000
CY2019 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.033
CY2018 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.000
CY2019 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
-0.030
CY2018 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
0.000
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.202
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.275
CY2019 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2018 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2019 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0 USD
CY2018 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0 USD
CY2019 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0 USD
CY2018 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0 USD
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
6020000 USD
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
16357000 USD
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
0 USD
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
0 USD
CY2018Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
0 USD
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
24000 USD
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
0 USD
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
12237000 USD
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
6020000 USD
CY2019Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1104000 USD
CY2018Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
0 USD
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
29722000 USD
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
6020000 USD
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
29722000 USD
CY2019 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
23700000 USD
CY2019Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 USD
CY2018Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 USD
CY2018 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
3000000.0 USD
CY2019Q2 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
16400000 USD
CY2019Q4 imux Operating Loss Carryforward Limitation On Use Amount
OperatingLossCarryforwardLimitationOnUseAmount
800000 USD
CY2019Q1 us-gaap Operating Expenses
OperatingExpenses
4662000 USD
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
15007000 USD
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
9177000 USD
CY2019Q4 us-gaap Operating Expenses
OperatingExpenses
8186000 USD
CY2019 us-gaap Operating Expenses
OperatingExpenses
37032000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-4313000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-14714000 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-8215000 USD
CY2019Q4 us-gaap Net Income Loss
NetIncomeLoss
-7691000 USD
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-34933000 USD
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-5.09
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.52
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.82
CY2019Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.75
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.52
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
2288000 USD
CY2018Q2 us-gaap Operating Expenses
OperatingExpenses
2670000 USD
CY2018Q3 us-gaap Operating Expenses
OperatingExpenses
1805000 USD
CY2018Q4 us-gaap Operating Expenses
OperatingExpenses
5234000 USD
CY2018 us-gaap Operating Expenses
OperatingExpenses
11997000 USD
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-2263000 USD
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-2670000 USD
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-1797000 USD
CY2018Q4 us-gaap Net Income Loss
NetIncomeLoss
-4812000 USD
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-11542000 USD
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.67
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.15
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.12
CY2018Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-5.68
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-13.63

Files In Submission

Name View Source Status
0001280776-20-000009-index-headers.html Edgar Link pending
0001280776-20-000009-index.html Edgar Link pending
0001280776-20-000009.txt Edgar Link pending
0001280776-20-000009-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
imux-123119xexhibit211.htm Edgar Link pending
imux-123119xexhibit231.htm Edgar Link pending
imux-123119xexhibit311.htm Edgar Link pending
imux-123119xexhibit312.htm Edgar Link pending
imux-123119xexhibit321.htm Edgar Link pending
imux-123119xexhibit322.htm Edgar Link pending
imux-20191231.htm Edgar Link pending
imux-20191231.xsd Edgar Link pending
imux-20191231_cal.xml Edgar Link unprocessable
imux-20191231_def.xml Edgar Link unprocessable
imux-20191231_g1.jpg Edgar Link pending
imux-20191231_htm.xml Edgar Link completed
imux-20191231_lab.xml Edgar Link unprocessable
imux-20191231_pre.xml Edgar Link unprocessable
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending